Page 77 - Read Online
P. 77

Judson. J Cancer Metastasis Treat 2021;7:28  https://dx.doi.org/10.20517/2394-4722.2021.110  Page 5 of 5

               Conflicts of interest
               The author declares that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.       Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N
                   Engl J Med 2002;347:472-80.  DOI  PubMed
               2.       Smith S, Reeves BR, Wong L, Fisher C. A consistent chromosome translocation in synovial sarcoma. Cancer Genet Cytogenet
                   1987;26:179-80.  DOI  PubMed
               3.       Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-
                   associated box in human synovial sarcoma. EMBO J 1995;14:2333-40.  PubMed  PMC
               4.       Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial
                   sarcoma. Cell 2013;153:71-85.  DOI  PubMed  PMC
               5.       McBride MJ, Pulice JL, Beird HC, et al. The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive
                   synovial sarcoma. Cancer Cell 2018;33:1128-41.e7.  DOI  PubMed  PMC
               6.       Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas With CIC-rearrangements are a distinct pathologic entity with aggressive
                   outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol 2017;41:941-9.  DOI  PubMed  PMC
               7.       Schöffski P, Sufliarsky J, Gelderblom H, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours
                   with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101
                   CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med 2018;6:431-41.  DOI  PubMed
               8.       Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an
                   international, open-label, phase 2 basket study. Lancet Oncol 2020;21:1423-32.  DOI  PubMed
               9.       Karolak M, Tracey I, Shipley J, Walters ZS. Targeting EZH2 for the treatment of soft tissue sarcomas. J Cancer Metastasis Treat
                   2021;7:15.  DOI
               10.      Abe K, Shimozaki S, Domoto T, et al. Glycogen synthase kinase 3ß biology in bone and soft tissue sarcomas. J Cancer Metastasis
                   Treat 2020;6:51.  DOI
               11.      Walz A, Ugolkov A, Chandra S, et al. Molecular pathways: revisiting glycogen synthase kinase-3beta as a target for the treatment of
                   cancer. Clin Cancer Res 2017;23:1891-7.  DOI  PubMed  PMC
               12.      Shimozaki S, Yamamoto N, Domoto T, et al. Efficacy of glycogen synthase kinase-3beta targeting against osteosarcoma via activation
                   of beta-catenin. Oncotarget 2016;7:77038-51.  DOI  PubMed  PMC
               13.      Abe K, Yamamoto N, Domoto T, et al. Glycogen synthase kinase 3beta as a potential therapeutic target in synovial sarcoma and
                   fibrosarcoma. Cancer Sci 2020;111:429-40.  DOI  PubMed  PMC
               14.      Tran DTP, Kuchimaru T, Pongsuchart M, et al. ROR2 regulates the survival of murine osteosarcoma cells in lung capillaries. J Cancer
                   Metastasis Treat 2020;6:47.  DOI
               15.      Pacheco M, Righi A. Primary malignant tumors of bone surface: a review with emphasis on differential diagnosis. J Cancer Metastasis
                   Treat 2020;6:49.  DOI
               16.      Pinanamaneni S, Damron TA. Proximal humerus reconstruction in orthopaedic oncology. J Cancer Metastasis Treat 2021;7:7.  DOI
               17.      Baker LH, Boonstra PS, Reinke DK. Burden of chronic diseases among sarcoma survivors treated with anthracycline chemotherapy:
                   results from an observational study. J Cancer Metastasis Treat 2020;6:24.  DOI
               18.      Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with
                   high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet
                   Oncol 2017;18:812-22.  DOI  PubMed
               19.      Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-
                   risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010;11:950-
                   61.  DOI  PubMed  PMC
               20.      Kopp LM, Womer RB, Schwartz CL, et al. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant
                   neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. Cardiooncology 2019;5:15.  DOI  PubMed
                   PMC
   72   73   74   75   76   77   78   79   80   81   82